Figure 1.
Figure 1. Clinical outcomes in patients with high-risk smoldering myeloma after 8 cycles of KRd and 2 years of lenalidomide maintenance. Estimated (A) PFS and (B) OS.

Clinical outcomes in patients with high-risk smoldering myeloma after 8 cycles of KRd and 2 years of lenalidomide maintenance. Estimated (A) PFS and (B) OS.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal